A Phase I, Open Label Study of the Pharmacokinetics and Safety of Cediranib (RECENTINTM, AZD2171) Following Single and Multiple Oral Doses in Patients With Advanced Solid Tumours With Various Degrees of Hepatic Dysfunction
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).
Single dose PK assessed on Day 1 of dosing
No
CML van Herpen, MD
Principal Investigator
Radboud University
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
D8480C00032
NCT00621725
January 2008
June 2013
Name | Location |
---|